Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback